Breast Cancer Cells against HER-2-Overexpressing and Trastuzumab-Treated Activity of the Dual Kinase Inhibitor Lapatinib ( GW 572016 )

@inproceedings{Konecny2006BreastCC,
  title={Breast Cancer Cells against HER-2-Overexpressing and Trastuzumab-Treated Activity of the Dual Kinase Inhibitor Lapatinib ( GW 572016 )},
  author={Gottfried E. Konecny and Mark D. Pegram and Natarajan Venkatesan and Richard S. Finn and Guorong Yang and Martina Rahmeh and Michael Untch and David W. Rusnak and Glenn M Spehar and Robert J. Mullin and Barry R. Keith and Tona M. Gilmer and Mark Berger and Karl C. Podratz and Dennis J. Slamon},
  year={2006}
}
Lapatinib (GW572016) is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases. Here, we explore the therapeutic potential of lapatinib by testing its effect on tumor cell growth in a panel of 31 characterized human breast cancer cell lines, including trastuzumab-conditioned HER-2-positive cell lines. We further characterize its activity in combination with trastuzumab and analyze whether EGFR and HER-2 expression or changes induced in the activation of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 49 references

A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab [abstract 3043

  • HA III Burris, AM Storniolo, EA Overmoyer
  • Breast Cancer Res Treat 2004;88:S126
  • 2004
1 Excerpt

Similar Papers

Loading similar papers…